Cullinan Therapeutics Ownership | Who Owns Cullinan Therapeutics?

Cullinan Therapeutics Ownership Summary

Cullinan Therapeutics is owned by 41.16% institutional investors, 0.64% insiders, and 58.21% retail investors. Bioimpact capital is the largest institutional shareholder, holding 12.96% of CGEM shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.14% of its assets in Cullinan Therapeutics shares.

CGEM Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Cullinan Therapeutics	41.16%	0.64%	58.21%
Sector	Healthcare Stocks	232.01%	10.74%	-142.75%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Bioimpact capital	7.65M	12.96%	$45.35M
Lynx1 capital management lp	5.77M	9.77%	$34.19M
Bvf inc/il	5.75M	9.74%	$34.10M
Blackrock	3.55M	8.25%	$61.92M
Blackrock funding, inc. /de	4.40M	7.46%	$45.54M
Vanguard group	3.30M	5.59%	$34.14M
Deerfield management company, l.p. (series c)	2.93M	4.96%	$17.36M
Blue owl capital lp	2.35M	3.98%	$24.33M
Kynam capital management, lp	2.30M	3.90%	$13.65M
Orbimed advisors	1.92M	3.26%	$11.41M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Bioimpact capital	7.65M	7.42%	$45.35M
Lynx1 capital management lp	5.77M	6.96%	$34.19M
Nextech invest	1.14M	2.25%	$13.90M
Blue owl capital lp	2.35M	1.82%	$24.33M
Bvf inc/il	5.75M	1.38%	$34.10M
Nextech invest	1.14M	1.03%	$6.77M
Kynam capital management, lp	2.30M	1.02%	$13.65M
Boxer capital	657.89K	0.60%	$11.47M
Artal group	1.06M	0.47%	$18.45M
Vr adviser	1.38M	0.46%	$8.18M

Top Buyers

Holder	Shares	% Assets	Change
Lynx1 capital management lp	5.77M	6.96%	1.37M
Blackrock	3.55M	0.00%	1.12M
Artal group	1.06M	0.47%	1.06M
Boxer capital	657.89K	0.60%	657.89K
Morgan stanley	766.93K	0.00%	366.78K

Top Sellers

Holder	Shares	% Assets	Change
Paradigm biocapital advisors lp	-	-	-2.32M
Holocene advisors, lp	-	-	-1.53M
Franklin resources	-	-	-1.42M
Cormorant asset management, lp	-	-	-1.13M
Adage capital partners gp	-	-	-1.03M

New Positions

Holder	Shares	% Assets	Change	Value
Artal group	1.06M	0.47%	1.06M	$18.45M
Boxer capital	657.89K	0.60%	657.89K	$11.47M
Cubist systematic strategies	222.32K	0.01%	222.32K	$1.32M
Jump financial	194.51K	0.01%	194.51K	$1.15M
Susquehanna portfolio strategies	124.53K	0.01%	124.53K	$738.47K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-5.00
Capital performance advisors llp	-13.00
Versant capital management	-23.00
Corecap advisors	-29.00
True wealth design	-36.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	87	-40.00%	24,287,663	-60.24%	41	0.38%	54	-36.47%	24	-33.33%
Sep 30, 2025	141	2.92%	61,105,493	3.70%	103	1.04%	81	20.90%	35	-14.63%
Jun 30, 2025	144	-4.00%	62,598,313	-3.20%	106	0.88%	69	1.47%	44	-16.98%
Mar 31, 2025	19	-87.25%	31,573,885	-51.85%	53	0.43%	6	-92.68%	5	-86.11%
Dec 31, 2024	78	-45.07%	19,633,373	-69.80%	33	0.27%	44	-48.24%	22	-21.43%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	1.86M	3.14%	-
Vanguard US Total Market Shares ETF	1.50M	2.57%	-
iShares Russell 2000 ETF	1.30M	2.21%	667.60K
State Street® SPDR® S&P® Biotech ETF	1.06M	1.79%	-5.70K
Franklin Small Cap Growth SMA	849.95K	1.44%	849.91K
Franklin US Small Cap Growth Equity	849.95K	1.44%	64.90K
Franklin Biotechnology Discv A(acc)USD	842.14K	1.43%	-
Franklin Small Cap Growth Adv	785.04K	1.33%	-
AB Small Cap Growth A	750.85K	1.27%	-21.14K
Vanguard Institutional Extnd Mkt Idx Tr	563.42K	0.95%	3.04K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 05, 2026	Michaelson Jennifer	Chief Scientific Officer	Sell	$125.44K
Feb 25, 2026	Michaelson Jennifer	Chief Scientific Officer	Sell	$25.17K
Feb 23, 2026	Michaelson Jennifer	Chief Scientific Officer	Sell	$24.51K
Feb 24, 2026	Michaelson Jennifer	Chief Scientific Officer	Sell	$52.11K
Feb 24, 2026	AHMED NADIM	President and CEO	Sell	$195.56K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	14
2025 Q4	8	8
2025 Q3	-	-
2025 Q2	-	-
2025 Q1	-	5

CGEM Ownership FAQ

Who owns the most shares of Cullinan Therapeutics?

Cullinan Therapeutics’s largest shareholders are Bioimpact capital (7.65M shares, 12.96%), Lynx1 capital management lp (5.77M shares, 9.77%), and Bvf inc/il (5.75M shares, 9.74%). Together, they hold 32.47% of Cullinan Therapeutics’s total shares outstanding.

Does Blackrock own Cullinan Therapeutics?

Yes, BlackRock owns 8.25% of Cullinan Therapeutics, totaling 3.55M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 61.92M$. In the last quarter, BlackRock increased its holdings by 1.12M shares, a 46.16% change.

Who is Cullinan Therapeutics’s biggest shareholder by percentage of total assets invested?

Bioimpact capital is Cullinan Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.42% of its assets in 7.65M Cullinan Therapeutics shares, valued at 45.35M$.

Who is the top mutual fund holder of Cullinan Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Cullinan Therapeutics shares, with 3.14% of its total shares outstanding invested in 1.86M Cullinan Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools